The stock of Bright Minds Biosciences Inc. (NASDAQ:DRUG) last traded at $0.77, down -3.57% from the previous session.
Data from the available sources indicates that Bright Minds Biosciences Inc. (NASDAQ:DRUG) is covered by 1 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $9.09 and a low of $9.09, we find $9.09. Given the previous closing price of $0.79, this indicates a potential upside of 1050.63 percent. DRUG stock price is now -17.60% away from the 50-day moving average and -29.69% away from the 200-day moving average. The market capitalization of the company currently stands at $19.27M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
In total, 0 analysts have assigned it a hold rating, and 1 have given it a buy rating. Brokers who have rated the stock have averaged $9.09 as their price target over the next twelve months.
.
Insiders disposed of 10,000 shares of company stock worth roughly $7700.0 over the past 1 year. A total of 23.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DRUG stock. A new stake in Bright Minds Biosciences Inc. shares was purchased by FIRST REPUBLIC INVESTMENT MANAGEMENT, INC. during the first quarter worth $9,000. TWO SIGMA INVESTMENTS, LP invested $8,000 in shares of DRUG during the first quarter. In the first quarter, BANK OF AMERICA CORP /DE/ acquired a new stake in Bright Minds Biosciences Inc. valued at approximately $8,000. TWO SIGMA SECURITIES, LLC acquired a new stake in DRUG for approximately $8,000. In total, there are 13 active investors with 2.23% ownership of the company’s stock.
With an opening price of $0.8000 on Tuesday morning, Bright Minds Biosciences Inc. (NASDAQ: DRUG) set off the trading day. During the past 12 months, Bright Minds Biosciences Inc. has had a low of $0.70 and a high of $4.75. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 8.10, and a quick ratio of 8.10. The fifty day moving average price for DRUG is $0.9297 and a two-hundred day moving average price translates $1.0896 for the stock.
The latest earnings results from Bright Minds Biosciences Inc. (NASDAQ: DRUG) was released for Jun, 2022.
Bright Minds Biosciences Inc.(DRUG) Company Profile
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
